Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer

Biochemical Pharmacology, Journal Year: 2023, Volume and Issue: 210, P. 115459 - 115459

Published: Feb. 20, 2023

Language: Английский

---

Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: July 2, 2024

Abstract Breast cancer (BC) has a high mortality rate and is one of the most common malignancies in world. Initially, BC was considered non-immunogenic, but paradigm shift occurred with discovery tumor-infiltrating lymphocytes (TILs) regulatory T cells (Tregs) tumor microenvironment. CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) immunotherapy emerged as treatment option for BC, it limitations, including suboptimal antitumor effects toxicity. Research demonstrated that anti-CTLA-4 combination therapies, such Treg depletion, vaccines, modulation gut microbiome, are significantly more effective than monoclonal antibody (mAB) monotherapy. Second-generation antibodies currently being developed to mitigate immune-related adverse events (irAEs) augment efficacy. This review examines mAB both monotherapy other treatments, sheds light on ongoing clinical trials, novel therapeutic strategies, potential utility biomarkers BC. Graphical

Language: Английский

---

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

World Journal of Surgical Oncology, Journal Year: 2021, Volume and Issue: 19(1)

Published: Sept. 2, 2021

Studies on PD-L1 expression in breast cancer have gained importance recent years, especially triple-negative (TNBC). Our aim was to analyze the differential of explore its correlation with response neoadjuvant chemotherapy (NACT) and patient survival.PD-L1 evaluated immunohistochemically (Ventana SP263 clone kit) by staining tumor specimen. positivity defined as membranous > 1%, 5%, 10%, 20% either cell (TC) /or immune (IC).Fifty patients locally advanced TNBC, who had a partial NACT, were included study. observed TCs 25 (50%) ICs 23 (46%) when 1% considered positive. Patients more likely respond measured "MD Anderson Cancer Center Residual Burden Index" (14/22, 63.6% vs. 10/27, 37%, p = 0.064). The 5-year disease-free survival (DFS) disease-specific (DSS) rates 46.3% 51.4%, respectively. A high (> 20%) tumoral associated better DFS DSS.Studies literature mostly focused inflammatory cells. However, our results suggest that outcome. Since residual burden express TILs an checkpoint inhibitor therapy addition NACT would be important option for TNBC disease.

Language: Английский

---

Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis

Cancers, Journal Year: 2021, Volume and Issue: 13(5), P. 942 - 942

Published: Feb. 24, 2021

The formation of new blood (angiogenesis) and lymphatic (lymphangiogenesis) vessels are major events associated with most epithelial malignancies, including breast cancer. Angiogenesis is essential for cancer cell survival. Lymphangiogenesis critical in maintaining tumoral interstitial fluid balance importing tumor-facilitatory immune cells. Both vascular routes also serve as conduits metastasis. Intratumoral hypoxia promotes both by stimulating multiple angiogenic/lymphangiogenic growth factors. Studies on tumor-associated lymphangiogenesis its exploitation therapy have received less attention from the research community than those angiogenesis. Inflammation a key mediator processes, hijacked many cancers aberrant expression inflammation-associated enzyme cyclo-oxygenase (COX)-2. In this review, we focus showed that COX-2 promoter events, primarily resulting activation prostaglandin (PG) E receptor EP4 tumor cells, tumor-infiltrating endothelial cells; induction oncogenic microRNAs. COX-2/EP4 pathway additional progression, such migration, invasion, stimulation stem-like Based combination studies using models, show antagonists hold promise other modalities check-point inhibitors.

Language: Английский

---

Eco-Friendly Nanotherapeutics: Metallic Nanoparticles for Targeting Breast Cancer

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177603 - 177603

Published: April 1, 2025

Language: Английский

---